Klarquist et al. found that the vaccination of CCL22 led to redirecting Treg away from tumors, and the repetitive vaccination with CCL22 sufficiently limited Treg accumulation and tumor growth in animals, which carried the potential of local vaccination of CCL22 to enhance the therapeutic effect of ICIs (Klarquist et al., 2016). This evidence concerns the gene CCL22 and neoplasm.